First-pass extracted concept

CRISPR-based gene editing technologies

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

CRISPR-based gene editing technologies provide new therapeutic avenues by enabling the precise correction of HBB mutations or the reactivation of fetal hemoglobin (HbF) through the targeting of regulatory elements such as BCL11A.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1delivery challengesupports2025Source 1DOI PubMed

Efficient and safe delivery remains a major challenge for CRISPR-based β-thalassemia therapies.

Claim 2evidence statussupports2025Source 1DOI PubMed

CRISPR-based therapeutic approaches for β-thalassemia have shown promising preclinical and clinical outcomes.

Claim 3therapeutic rationalesupports2025Source 1DOI PubMed

CRISPR-based gene editing technologies provide therapeutic avenues for β-thalassemia by enabling precise correction of HBB mutations or reactivation of fetal hemoglobin through targeting regulatory elements such as BCL11A.